"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 3 | 1 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
A pH-Responsive and Guanidinium-Rich Nanoadjuvant Efficiently Delivers STING Agonist for Cancer Immunotherapy. ACS Nano. 2025 Feb 25; 19(7):6758-6770.
-
Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun. 2024 Dec 16; 15(1):10683.
-
Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma. Front Immunol. 2024; 15:1442673.
-
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors. Am J Clin Oncol. 2024 Nov 01; 47(11):517-525.
-
Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval. Clin Transl Oncol. 2024 Aug; 26(8):1908-1920.
-
Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors. BMC Cancer. 2023 Jul 13; 23(1):655.
-
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clin Cancer Res. 2023 05 15; 29(10):1938-1951.
-
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022 07 01; 132(13).
-
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci Adv. 2022 Mar 04; 8(9):eabm1032.
-
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 Sep 23; 12(1):5606.